We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


OGT Grants Microarray License to Invitrogen for Microarray Services

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OGT Grants Microarray License to Invitrogen for Microarray Services"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Oxford Gene Technology (OGT) and Invitrogen Corporation have announced the completion of a licence agreement granting Invitrogen access to one of OGT’s "Southern array patents", the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.

The granted license will enable Invitrogen to offer DNA related microarray services, worldwide, from its US operations.    

Sue Sutton, Vice President Licensing North America, at OGT said, "Successful discussions with Invitrogen have concluded with the granting of this license thus enabling a world class company such as Invitrogen to expand their service base and adding to OGT’s growing portfolio of North American licensees."

Amy Butler, Vice President of Invitrogen’s Gene Expression Profiling business, commented that, "Invitrogen continually strives to provide complete and optimised solutions to its customers in terms of both its products and its services."

"This agreement will enable Invitrogen to provide a more complete offering to its customers who are interested in microarray services."
The licence will remain valid for the patents’ lifetime.